BPA
ACAD icon

Beacon Pointe Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Beacon Pointe Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-29,157
Closed -$408K – 995
2022
Q2 		$408K Sell
29,157
-6,200
-18% -$116K 0.01% 716
2022
Q1 		$856K Buy
35,357
+9,200
+35% +$223K 0.01% 667
2021
Q4 		$611K Sell
26,157
-15,298
-37% -$308K 0.02% 500
2021
Q3 		$689K Sell
41,455
-9,150
-18% -$176K 0.02% 471
2021
Q2 		$1.23M Buy
+50,605
New +$1.14M 0.04% 301

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Beacon Pointe Advisors's ACAD Position: Q3 2022 in Review

Beacon Pointe Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q3 2022, closing a stake of 29,157 shares — an estimated $408K sold.

Beacon Pointe Advisors first reported a position in ACAD in Q2 2021 and held it in 5 quarters. The position peaked at $1.23M in Q2 2021. 223 funds tracked by Wall St. Rank hold ACAD as of Q3 2022.

  • Beacon Pointe Advisors reported no remaining Acadia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Beacon Pointe Advisors sold 29,157 Acadia Pharmaceuticals shares in Q3 2022, an estimated $408K.
  • Beacon Pointe Advisors first reported a position in Acadia Pharmaceuticals in Q2 2021 and held it in 5 quarters.
  • Beacon Pointe Advisors's Acadia Pharmaceuticals position peaked at $1.23M in Q2 2021.
  • 223 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2022.

Based on Beacon Pointe Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.